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Computational simulation of the predicted
dosimetric impact of adjuvant yttrium-90
PET/CT-guided percutaneous ablation
following radioembolization
Alexander S. Pasciak1,2*, Abigail Lin2, Christos Georgiades3, Laura K. Findeiss1, Shannon Kauffman4
and Yong C. Bradley1
Abstract
Background: 90Y PET/CT post-radioembolization imaging has demonstrated that the distribution of 90Y in a tumor
can be non-uniform. Using computational modeling, we predicted the dosimetric impact of post-treatment 90Y
PET/CT-guided percutaneous ablation of the portions of a tumor receiving the lowest absorbed dose. A cohort of
fourteen patients with non-resectable liver cancer previously treated using 90Y radioembolization were included in
this retrospective study. Each patient exhibited potentially under-treated areas of tumor following treatment based
on quantitative 90Y PET/CT. 90Y PET/CT was used to guide electrode placement for simulated adjuvant radiofrequency
ablation in areas of tumor receiving the lowest dose. The finite element method was used to solve Penne’s bioheat
transport equation, coupled with the Arrhenius thermal cell-death model to determine 3D thermal ablation zones.
Tumor and unablated tumor absorbed-dose metrics (average dose, D50, D70, D90, V100) following ablation were
compared, where D70 is the minimum dose to 70% of tumor and V100 is the fractional tumor volume receiving more
than 100 Gy.
Results: Compared to radioembolization alone, 90Y radioembolization with adjuvant ablation was associated with
predicted increases in all tumor dose metrics evaluated. The mean average absorbed dose increased by 11.2 ± 6.9 Gy.
Increases in D50, D70, and D90 were 11.0 ± 6.9 Gy, 13.3 ± 10.9 Gy, and 11.8 ± 10.8 Gy, respectively. The mean increase in
V100 was 7.2 ± 4.2%. All changes were statistically significant (P < 0.01). A negative correlation between pre-ablation
tumor volume and D50, average dose, and V100 was identified (ρ < − 0.5, P < 0.05) suggesting that adjuvant
radiofrequency ablation may be less beneficial to patients with large tumor burdens.
Conclusions: This study has demonstrated that adjuvant 90Y PET/CT-guided radiofrequency ablation may improve
tumor absorbed-dose metrics. These data may justify a prospective clinical trial to further evaluate this hybrid approach.
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Background
Tumor targeting in yttrium-90 (90Y) radioembolization
differs from other radionuclide therapies that are infused
systemically and find their targets through high affinity to
cellular receptors. Instead, the distribution of 90Y within a
tumor depends strongly on the catheter position during
infusion, downstream fluid dynamics, and arterial perfu-
sion in both tumor and uninvolved liver [1, 2]. Due to the
mechanical nature of 90Y microsphere trapping, dose non-
uniformities within tumor have been demonstrated
through histological analyses [3–6] and 90Y PET/CT im-
aging [7–10]. While several metrics have been used to
predict response following radioembolization [11], average
tumor absorbed dose (Davg) is the most common metric.
However, non-uniform deposition of 90Y may result in a
sub-therapeutic dose to portions of the tumor, which has
been shown to correlate with poor response even if Davg is
favorable [9].
Like many liver-directed therapies, 90Y radioemboliza-
tion is commonly classified as a palliative treatment due
to the relatively poor prognosis of patients with liver
cancer. However, this does not suggest that there is no
utility in treatment optimization. Response following
locoregional hepatic therapy has been shown to correlate
with improved patient survival, prompting the use of
multimodality therapies [12, 13] to improve tumor re-
sponse. One such example of multimodality therapy is
combined trans-arterial chemoembolization (TACE) and
radiofrequency ablation (RFA) for the treatment of hepa-
tocellular carcinoma (HCC) [12]. Since the widespread
use of post-radioembolization 90Y PET/CT, there has been
an interest in utilizing this imaging data to improve pa-
tient therapy. While multimodality treatment utilizing 90Y
radioembolization has not been widely studied, several
authors have attempted the use of 90Y PET/CT to provide
multistage patient-specific 90Y treatments with positive
outcomes [14, 15].
Image-guided percutaneous ablation is the standard
minimally invasive treatment for eligible patients with
small (<3 cm) liver tumors [16]. However, the efficacy of
ablation decreases with increasing tumor size. For patients
with HCC, RFA generally results in poor outcomes for
tumors greater than 5 cm in size, where alternative treat-
ments such as 90Y radioembolization are commonly
employed [17]. While combined RFA and TACE has
demonstrated improved response in treating larger tumors
[12], the utility of combining percutaneous ablation with
90Y radioembolization has not yet been evaluated. 3D 90Y
PET/CT-based dosimetry and dose–response thresholds
[18, 19] may be used in principle as a guide for percutan-
eous ablation of under-treated regions of tumor, poten-
tially improving therapy.
In this work, 90Y PET/CT has been used as a guide for
simulated modeling of adjuvant RFA. Improvement in
tumor absorbed-dose metrics in the unablated tumor
has been calculated to determine if this hybrid technique
warrants further evaluation in a prospective clinical trial.
Methods
The study was carried out in compliance with the Dec-
laration of Helsinki and has been approved by the insti-
tutional review board at each participating site. Written
consent was obtained from patients at site A (University
of Tennessee IRB #3502), while a waiver of informed
consent was obtained for data collected at site B (Wright
State University IRB #SC6291). Patients treated with 90Y
radioembolization using resin [site A, SIR-Spheres®, SIR-
Tex Medical Ltd, North Sydney, Australia] or glass [site
B, Therasphere® BTG, London, UK] microspheres for
primary or secondary liver cancer and who received
post-treatment 90Y PET/CT imaging were reviewed.
Fourteen patients (age 49–80 years) met the inclusion
criteria of tumor D70 < 100 Gy [9] for resin micro-
spheres (D70 < 150 Gy for glass) with visualized areas
of decreased microsphere uptake >2 cm in size identi-
fied on 90Y PET/CT, where D70 is the minimum
absorbed dose (Gy) to 70% of the tumor volume. These
patients received radioembolization for treatment of
hepatocellular carcinoma (HCC, n = 10), intrahepatic
cholangiocarcinoma (n = 2), or liver dominant meta-
static disease (n = 2). The median model for end-stage
liver disease score was 8, with 10 Child-Pugh class A
patients and 4 class B patients. Additional data are
available in Table 1.
Table 1 Patient demographic and 90Y radioembolization
treatment data






1 HCC 124.1 Resin 1.30
2 HCC 270.4 Resin 1.39
2 HCC 241.3 Resin 1.39
3 HCC 276.4 Resin 1.67
4 Cholangio 100.7 Resin 0.62
5 HCC 374.6 Resin 1.24
6 Cholangio 44.4 Resin 0.92
7 Endometrial 203.2 Resin 1.14
8 HCC 220.9 Resin 1.01
9 HCC 213.4 Resin 1.83
10 HCC 42.5 Resin 1.54
11 Breast 60.2 Resin 1.17
12 HCC 104.7 Glass 2.51
13 HCC 323.4 Glass 4.13
14 HCC 258.2 Glass 3.23
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Dosimetry
Patients treated at site A (resin microspheres) were
scanned on a Siemens Biograph mCT Flow [Siemens
Healthcare, Knoxville, TN] with a bed speed of 0.2 mm/s
and reconstructed with 3D OSEM, 2i21s, time-of-flight, a
400 × 400 matrix (2.0 mm voxels), and no filter. Patients
treated at site B (glass microspheres) were scanned on a
GE Discovery 600 STE [GE Healthcare, Little Chalfont,
UK] using two bed positions, 20 min per position, 3D
OSEM, 2i24s, a 192 × 192 matrix (2.6 mm voxels), and no
filter. 90Y imaging performance of these PET/CT scanners
at activity concentrations common in radioembolization
with resin microspheres has been evaluated previously
[20]. All patients received post-radioembolization 90Y
PET/CT imaging on the day of treatment.
Under the supervision of a dual-board-certified nuclear
medicine radiologist, tumors were contoured in three
dimensions on 90Y PET/CT referencing appropriate pre-
treatment hepatic protocol CT or MRI in patients with
HCC or 18FDG PET/CT images in patients with meta-
static disease. Contours were drawn using Osirix 7.5
[Pixmeo, Bernex, CH], exported to Matlab 2014b [Math-
works, Natick, MA], and converted to a 3D mask with the
same pixel size as 90Y PET/CT data. For each tumor, 90Y
PET/CT-based 3D dosimetry was performed using the
local deposition method [21] and dose–volume histograms
were generated. The D50, D70, D90, maximum and aver-
age tumor dose (Davg), and V100 were calculated for each
tumor since these metrics were previously validated as
prognostic indices for radioembolization [9], where D50
and D90 are the minimum doses to 50 and 90% of tumor
volume and V100 is the percentage of tumor volume
receiving more than 100 Gy.
Radiofrequency ablation simulation
Because RFA is the most common treatment in the USA
for small tumor ablation in situ [16], it was selected as
the simulated ablation modality in this study. While
in vivo and ex vivo RF temperature profiles and ablation
zones have been published previously, we elected to use
biophysical modeling which allowed for flexible calcula-
tion of ablation zones for varied ablation times, elec-
trode angles, positions, and tumor tissue characteristics
(HCC or metastatic disease) which could be defined in a
3D voxel space matching that of 90Y PET/CT. This
model was compared with data previously reported from
similar models [22] and in vivo measurements [23] to
establish its accuracy under a fixed set of conditions.
The model consisted of a water-cooled 17-gauge
straight RF electrode with a 30-mm active tip. The elec-
trode model was placed inside a 20 × 20 × 20 cm block
of liver tissue, with electrothermal properties discussed
later in this section. A 3D tetrahedral mesh was applied
to the model for finite element method (FEM) analysis
of the heat transport problem. The maximum mesh
element size was restricted to 8 mm in tissue, 1 mm in
the insulating portion of the electrode, and 0.25 mm in
the active electrode tip. The electrode model and tetra-
hedral mesh are shown in Fig. 1. The FEM was used to
solve Penne’s bioheat transport equation [24], which
consists of two partial differential equations:




¼ ∇ k∇Tð Þ þ wbcb T a−Tð Þ þ qm ð2Þ
where ∇ is the Laplace operator, σ is the electrical
conductivity (S/m), V is the electric potential (volts),
ρ is tissue material density (Kg/m3), c is tissue spe-
cific heat (J/Kg/°C), k is the electrical conductivity of
tissue (W/m/°C), wb is the perfusion rate of blood
per unit volume of tissue (m3/m3/s), and cb is the
specific heat of blood (J/Kg/°C). Ta is the temperature
of arterial blood, held constant at 37 °C, and T is the
temperature as a function of time, t. The initial con-
ditions for all geometries at all nodes (tissue and elec-
trode) were set to 37 °C, with liver boundary
conditions maintained at 37 °C throughout the simu-
lation. The potential (V) was modulated using a simu-
lated feedback circuit to maintain the temperature at
the hottest tissue node to <105 °C. The perfusion rate
of blood per unit volume in tissue (wb) was varied
during simulation to account for vascular coagulation
[25]. The first-order kinetic Arrhenius model [25] was
employed to estimate fractional vascular coagulation
Fig. 1 Model of actively cooled RF ablation electrode with
tetrahedral mesh applied for FEM-based solution of the Penne’s
bioheat transport equation (left). Simulated heating around electrode
in HCC (Table 2) with RF ablation cell killing boundary (Ω = 6.9) axial
and lateral range indicated (right)
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as a function of time and temperature during ablation, as









Cf is the fraction of capillary flow that has been oc-
cluded, and R is the ideal gas constant (8.314 J/mol/°K).
A is the Arrhenius pre-exponential factor, a measure of
molecular collision frequency (1.98e106 1/s), and Ea is
the activation energy, the amount of energy required to
transform molecules from their original state to a dam-
aged state (6.67e5 J/mol). T(t) is the temperature as a
function of time. Following a previous investigation [25],
Wb was linearly decreased with increasing Cf (Eq. 4) to
simulate decreasing blood perfusion as RFA creates
localized coagulation.
wb ¼ wb;nc 1−Cf
  ð4Þ
In Eq. 4, wb,nc is the perfusion rate of blood in the
absence of any heat-induced vascular coagulation. The
Penne’s heat transport equation [24] and similar approx-
imations have been previously used for modeling of
radiofrequency ablation in tissue, with several examples
[22, 26] reviewing additional relevant details.
The RFA electrode model, tetrahedral mesh, and
FEM analysis of the Penne’s bioheat equation were
simulated as described using COMSOL (FEMLAB)
5.0 [COMSOL, Stockholm, Sweden]. Electrode angle,
depth, ablation time, and tissue parameters were pre-
defined through a Matlab interface with COMSOL for
each location simulated. After each simulation, con-
tinuous temperature data as a function of time was
re-binned in Matlab into a 3D spatial map with voxel
sizes matching radioembolization data from quantita-
tive 90Y PET/CT. Calculations were performed on a
6th-generation Intel Core-i7 system with 32 Gb of
memory.
Tissue parameters
Tissue parameters (σ, ρ, c, k, cb, wb,nc) were obtained
from the literature for normal liver, cirrhotic liver, and
HCC (Table 2). Tissue parameters for normal liver were
used for the four patients treated for metastatic disease
or cholangiocarcinoma (Table 1) since no data specific
to these tumor types were available. Data for HCC were
used for simulation in the remaining patients. For ref-
erence, data for cirrhotic liver, with characteristically
decreased wb,nc, is also shown in Table 2.
90Y PET/CT-Guided RFA
The tumor destruction boundary corresponding to each
ablation location was calculated using the Arrhenius
model for cell killing from FEM calculated time-
dependent temperature (Eq. 5).





RT tð Þdt ð5Þ
When applied to the prediction of thermal cell death,
the Arrhenius pre-exponential factor (A) is 2.984e80 1/s,
the activation energy (Ea) is 5.06e5 J/mol, and SF is the
surviving fraction of cells. An Ω value of 6.9 was
selected, corresponding to a SF of 0.001 or 99.9% cell
killing within the ablation zone.
Under the supervision of a board-certified interven-
tional radiologist, up to four electrode locations were
selected in each patient, with ablation time up to 600 s
per location. Electrode locations were selected using
realistic percutaneous access paths, as would be per-
formed using conventional clinical techniques [16] under
CT or CT fluoroscopy guidance, with the acquired 90Y
PET/CT as a guide. Time and position were varied to limit
the ablation zone to areas of tumor receiving <100 Gy
when possible and, in cases where the ablation zone was
close to the liver capsule or gallbladder, to spare these
tissues. The ablation zone boundary was maintained at
least 1 cm from nearby gastrointestinal tissue.
Dosimetry with and without RFA
Following calculation of 3D ablation zones for each loca-
tion, the Ω = 6.9 threshold was used to create a 3D mask
of the absolute ablation boundary. This mask was
subtracted from the pre-defined tumor mask, leaving
unablated tumor, treated only with 90Y radioemboliza-
tion. Dose–volume histograms (DVH), D50, D70, D90,
Davg, and V100 were recomputed using the same 3D
dosimetric dataset (less ablated tissue) to compare 90Y
radioembolization with adjuvant PET/CT-guided abla-
tion to radioembolization alone in this patient cohort.
Statistical analysis
The Kolmogorov–Smirnov test was used to assess the
assumption of normality for all datasets evaluated. Dif-
ferences in tumor dose metrics between 90Y radioembo-
lization and 90Y radioembolization with PET/CT-guided
ablation were evaluated using a paired-sample T test.
The potential correlation between both tumor size and
number of ablation sites on post 90Y PET/CT-guided
ablation dose metrics was assessed using the Spearman’s
correlation statistic. Linear regression was used to ex-
plore this relationship if Spearman’s statistic suggested a
correlation (|ρ| > 0.5). A P value <0.05 was considered
statistically significant through all analysis.
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Results
Thirty-three RFA simulations were performed for the
adjuvant simulated therapy of 15 tumors. The mean
computation time per simulation was 7.8 min. Simulated
90Y PET/CT-guided RFA resulted in a calculated de-
crease in active tumor volume when cell killing inside
the Ω = 6.9 boundary was assumed. The mean pre- and
post-ablation tumor volume was 197.2 ± 102.3 cm3 and
179.3 ± 98.7 cm3, respectively. The average percent
decrease in tumor volume was 12.1 ± 7.9%. Spearman’s
statistic showed a moderate positive correlation between
the number of ablation sites and the absolute change in
tumor volume (ρ = 0.59, P = 0.02). Ablation and volumet-
ric data for each tumor is shown in Table 3. Lack of
consistency in the volumetric effect of ablation is
secondary to varying overlap of ablation zones or abla-
tion zones not fully contained within tumor boundaries.
Tumor dose
90Y PET/CT, particularly when converted to isodose
contour plots at the 100-Gy level (Figs. 2c and 3c) or
when the lower window level was set to 100 Gy, pro-
vided a clear guide for ablation. Examples of electrode
placement for targeting of under-treated regions in two
tumors spanning the full range of cohort tumor volume
(patients 1 and 5, Table 1) are shown in Figs. 2 and 3.
Adjuvant simulated ablation had the effect of modifying
the shape of the DVH, reducing the percentage of tumor
volume receiving lower absorbed doses in all cases.
However, the effect was more pronounced for smaller
tumors than larger tumors, as illustrated in Fig. 4a, b for
patients 1 and 5, respectively.
In addition to affecting DVH shape, simulated 90Y PET/
CT-guided RFA resulted in statistically significant in-
creases in the Davg, D50, D70, D90, and V100 compared
Table 2 Tissue parameters used in RF ablation simulation
σ (S/m)a ρ (Kg/m3)b c (J/Kg/°C)c k (W/m/°C)c wb,nc (m
3/m3/s), [(mL/min/100 mL)] cb (J/Kg/°C)
c
Normal liver 0.260 ± 0.062 1060 3540 ± 118 0.52 ± 0.03 0.0180 ± 0.0057
[108 ± 34.0]d
3617 ± 301
Cirrhotic liver 0.260 ± 0.062 1040 3540 ± 118 0.52 ± 0.03 0.0115 ± 0.0050
[69.0 ± 30.0]d
3617 ± 301
Tumor (HCC) 0.504 ± 0.191 1060 3540 ± 118 0.52 ± 0.03 0.0155 ± 0.015
[92.8 ± 88.6]e
3617 ± 301
aData from Haemmerich et al. [35]
bData from International Commission of Radiation Units and Measures [36]
cData from Hasgall et al. [37]
dData from Schutt and Haemmerich [22]
eData from Sahani et al. [38]
Table 3 Summary of RF ablation locations and tumor volume change
Patient Number of ablation
sites






1 1 600 124.1 112.9 9.9
2a 3 600/600/600 270.4 239.7 12.8
2a 2 600/600 241.3 217.0 11.2
3 2 600/420 276.4 253.9 8.9
4 2 600/600 100.7 78.1 28.9
5 2 600/360 374.6 352.9 6.1
6 1 600 44.4 32.5 36.6
7 2 600/600 203.2 177.7 14.4
8 2 220/220 220.9 212.2 4.1
9 3 600/360/360 213.4 192.7 10.7
10 1 600 42.5 29.9 42.1







14 2 600/600 258.2 240.1 7.5
aPatient 2 had two large independent foci in different liver segments, which were treated independently in this analysis
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to 90Y radioembolization alone. The mean absolute in-
crease in Davg was 11.2 ± 6.9 Gy (P < 0.001). Mean
increases in D50, D70, and D90 were 11.0 ± 6.9 Gy (P <
0.001), 13.3 ± 10.9 Gy (P < 0.001), and 11.8 ± 10.8 Gy
(P < 0.01), respectively. The mean increase in V100 was
7.2 ± 4.2% (P < 0.001). Additional calculated dosimetric
details comparing radioembolization alone and radio-
embolization with simulated RFA are given in Table 4.
The limited volume of tumor that can be affected by
RFA is reflected in the difference in the percent change
in D50, D70, and D90. For example, D50 was increased
by an average of 11.2%, D70 by 18.1%, and D90 by
43.8%. Since D90 is the minimum dose to 90% of the
tumor volume, it shows the most drastic difference
since adjuvant RFA targets a relatively small fraction of
tumor volume receiving the lowest dose.
Correlation with tumor volume
Spearman’s statistic indicated a correlation between
pre-ablation tumor volume and the absolute change in
four tumor dose metrics (ΔD50, ΔD70, ΔDavg, ΔV100)
with adjuvant RFA. ΔD50 and ΔD70 exhibited a mod-
erate (ρ = −0.64, P = 0.01) and weak (ρ = −0.34, P =
0.21) negative correlation with increasing tumor vol-
ume, respectively. No correlation between ΔD90 and
tumor volume was observed (ρ = 0.14, P = 0.62), likely
Fig. 2 90Y PET/CT-guided treatment plan for patient 1 (Table 1). a Post-radioembolization 90Y PET/CT with tumor contour (green). b Pre-treatment
hepatic protocol CT. c 100, 120, and 150 Gy isodose curves computed from post-radioembolization 90Y PET/CT using the local deposition method.
d Electrode placement (dashed white line) and RF ablation cell killing boundary (solid white line, Ω = 6.9)
Fig. 3 90Y PET/CT-guided treatment plan for Patient 5 (Table 1). a Post-radioembolization 90Y PET/CT with tumor contour (green). b Pre-treatment
hepatic protocol CT. c 100-, 120-, and 150-Gy isodose curves computed from post-radioembolization 90Y PET/CT using the local deposition
method. d Electrode placement in-plane (dashed white line), electrode placed 10 mm inferior to displayed slice (dotted white line) and RF ablation
cell killing boundary (solid white line, Ω = 6.9)
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secondary to the sensitivity of D90 to the 10% of tumor
volume receiving the lowest dose, which was effected
by adjuvant ablation regardless of tumor size. ΔDavg
exhibited a moderate negative correlation (ρ = −0.54,
P = 0.04) and ΔV100 showed a strong negative correl-
ation (ρ = −0.8, P = 5.0e−4) with increasing tumor vol-
ume. Linear regression analysis for the dose metrics
showing moderate or better correlation (|ρ| > 0.5) is
summarized in Fig. 5. The P values in Fig. 5 confirm
rejection of the null hypothesis when the linear fit is
compared to a constant model. These analyses suggest
that the effect of adjuvant RFA on ΔD50, ΔD70, ΔDavg,
and ΔV100 is decreased with increasing tumor volume.
On the other hand, ΔD90 remains favorable independ-
ent of the tumor size.
Discussion
The distribution of 90Y radioembolization within the
tumor can only be partially controlled by the treating
physician, i.e., by careful microcatheter placement and
through modification of downstream fluid dynamics. It is
logical, therefore, to combine 90Y radioembolization with
an adjuvant treatment modality that can be more precisely
targeted, such as percutaneous ablation. Compared to
RFA alone, there is substantial evidence that multimodal-
ity treatments such as combined TACE-RFA can result in
improved survival in patients with intermediate size HCC
lesions [12, 27]. While there are obvious similarities be-
tween TACE–RFA and combined radioembolization–
RFA, it is the differences that warrant discussion within
the context of the findings in this manuscript.
The primary utility of 90Y PET/CT is that it allows for
proactive planning of alternative or adjuvant therapies
immediately following radioembolization [14]. While not
fully established, published absorbed-dose thresholds
[18, 19] and quantitative 90Y PET/CT can be used to
plan secondary therapies, potentially including the per-
cutaneous ablation of areas of tumor receiving low
absorbed dose. By the same token, areas of tumor re-
ceiving high absorbed doses can be spared superfluous
secondary intervention. Unlike combined TACE–RFA,
strict quantification of the change in absorbed dose, a
physical quantity related to tumor response, can be pre-
dicted prior to adjuvant ablation following radioemboli-
zation—as has been done in this work. To this end, this
study has demonstrated statistically significant improve-
ments in both unablated tumor absorbed-dose metrics
and DVH shape after simulated ablation following 90Y
treatment in a 14-patient cohort.
The primary endpoint of this effort was successful in
elucidating that improvement in unablated tumor dose
metrics following adjuvant ablation appear possible;
however, the clinical significance of this is unknown. In
addition, neither the technical feasibility nor the compli-
cation rate associated with these two therapies in tan-
dem has been evaluated. Because percutaneous ablation
is highly targeted and spares normal liver tissue, how-
ever, it is likely that complication rates will be low.
Radioembolization–RFA can be contrasted in theory to
patients who received both external beam radiation ther-
apy and 90Y radioembolization—a tandem treatment
with a notable increase in hepatic toxicity [28].
The relationship between improved tumor absorbed-
dose metrics and improved response has been demon-
strated in 90Y radioembolization [9, 18]. However, there
is sufficient variability in the dose–response thresholds
reported in the literature that a prediction of improved
treatment efficacy in the patient cohort analyzed in this
manuscript cannot be made. The effect of combined
radioembolization and percutaneous ablation on tumor
Fig. 4 Dose–volume histograms for 90Y radioembolization alone and
90Y radioembolization with 90Y PET/CT-guided ablation. a Patient 1
(Table 1), pre-treatment tumor volume = 124.1 cm3. b Patient 5
(Table 1), pre-treatment tumor volume = 374.6 cm3
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response must, therefore, be evaluated as part of a future
clinical trial. Such a trial focusing on outcomes would
also allow exploration into situations where the tumor
as a whole was grossly under-treated, but without sub-
stantial inhomogeneity. While adjuvant ablation in the
case of homogeneous tumor dose would not result in a
substantial change in dose metrics, outcomes may still
be affected due to the concomitant biological effects of
both treatment modalities.
One limitation of this study is that the only percutan-
eous ablation modality simulated was RFA. While RFA
was selected due to its wide use in hepatic tumor abla-
tion [16], radioembolization combined with other abla-
tion modalities may be associated with different results.
For example, the mean difference in pre- and post-RFA
tumor volume among all patients was 18.9 cm3 (Table 3).
This relatively small volume is not only due to lower ab-
lation times used to target only under-treated tumor in
some patients but also due to the relatively small RFA
ablation zone size. In addition, the correlation identified
between tumor volume and absolute change in several
tumor absorbed-dose metrics (ΔD50, ΔD70, ΔDavg,
ΔV100) can be at least partially attributed to RFA abla-
tion zone size. Alternatives such as microwave ablation
are associated with larger ablation volumes may result in
further improvement in unablated tumor absorbed-dose
metrics if used following radioembolization.
A second limitation is that electrothermal tissue char-
acteristics and in particular, wb,nc, can vary substantially
and have a marked impact on calculated and actual RF
ablation zone size [22]. To this end, it is likely that the
model employed in this work, utilizing wb,nc for normal
liver and HCC (Table 2), resulted in an underestimation
of the ablation zone size. One clinically well-known
phenomenon in the thermal ablation of small HCC
tumors in patients with cirrhosis is the “oven effect” [29]
in which the decreased blood perfusion rate (wb,nc) in
cirrhotic liver (Table 2) results in an increased ablation
zone size. Since blood perfusion carries heat away from
the electrode, it ultimately limits the ablation zone size
regardless of the modality of thermal ablation used.
However, in 90Y PET/CT-guided RFA, patients receive
radioembolization with glass or resin microspheres prior
to adjuvant ablation. The embolic nature of the micro-
spheres, resin greater than glass, may decrease tumor
blood perfusion and, therefore, could increase ablation
zone size beyond that simulated in this work. The oven
effect may be contributory to increased ablation zone
size in RFA-TACE [12]; however, the effects following
90Y radioembolization cannot be determined at this pre-
clinical stage.
Finally, this study has not considered the effects of
respiratory motion on the 90Y PET/CT acquisition,
tumor boundary delineation, calculated dose metrics, or
the potential effect of respiratory motion on clinical
electrode placement. Several studies [30, 31] have de-
scribed changes in tumor volume and SUV in 18FDG
PET/CT when respiratory gating was used. However,
investigation into the feasibility of respiratory gating in
90Y PET/CT has been limited to a few examples [32, 33].
The usefulness of 90Y PET respiratory gating may be
limited by the small branching ratio of positron emission
in 90Y [34] and the clinical difficulty of increasing an
already long acquisition time. Respiratory motion un-
doubtedly had an effect on the tumor dose metrics
reported for each patient in this manuscript; however,
the extent of which could not be quantified. As this ef-
fort proceeds into clinical investigation, more work into
the potential use of amplitude based gating in 90Y PET
[32] may be warranted and, at the very least, physicians
Table 4 A comparison of mean (μ), standard deviation (σ), and range for dose metrics evaluated with and without adjuvant 90Y
PET/CT-guided percutaneous ablation
90Y 90Y + RF ablation Absolute change (Δ) Percentage change (%)
Davg (Gy) μ ± σ 122.3 ± 39.5 133.5 ± 41.9 11.2 ± 6.9* 9.7 ± 6.7
Range 67.3 − 210.2 72.1 − 231.6 2.2 − 21.9 2.0 − 23.4
Dmax (Gy) μ ± σ 523.2 ± 326.9 523.2 ± 326.9 0 0
Range 223.1 − 1474.9 223.1 − 1474.9
D50 (Gy) μ ± σ 112.8 ± 43.3 123.8 ± 44.9 11.0 ± 6.9* 11.2 ± 8.5
Range 48.5 − 201.8 52.9 − 225.3 2.5 − 23.6 2.4 − 26.7
D70 (Gy) μ ± σ 77.9 ± 27.4 91.2 ± 32.4 13.3 ± 10.9* 18.1 ± 14.3
Range 32.6 − 113.9 36.0 − 148.9 2.7 − 36.2 3.0 − 54.2
D90 (Gy) μ ± σ 37.8 ± 18.1 49.7 ± 17.1 11.8 ± 10.8† 43.8 ± 55.5
Range 14.1 − 72.9 19.4 − 74.4 1.4 − 43.7 1.9 − 216.6
V100 (%) μ ± σ 52.8 ± 19.0 60.0 ± 18.2 7.2 ± 4.2* 16.9 ± 15.7
Range 18.9 − 74.3 21.0 − 81.6 2.1 − 17.9 4.4 − 64.2
*P < 0.001; †P < 0.01
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must be aware of the potential effects of motion on 90Y
PET data when planning adjuvant therapy.
Although this work precedes a clinical trial, the tim-
ing of radioembolization and subsequent ablation will
be of concern and warrants brief discussion. 90Y radio-
embolization is a permanent implant, delivering 97.5%
of its absorbed dose to tissue in the first 2 weeks after
infusion. However, because there is no biological re-
moval of 90Y, the absorbed dose is committed immedi-
ately after the microspheres are infused. In theory, the
timing, therefore, between 90Y treatment and ablation
is not critical so long as ablation is performed before
structural tumor changes occur creating deviation with
the ablation guidance model, i.e., the post-treatment
90Y PET/CT. One additional concern is whether heat-
ing of microspheres in situ could result in the release
of free 90Y—a complication that must be investigated
with in vitro experiments and patient bioassay before
and during a future clinical trial. However, even if
systemic release is found to be a potential issue, wait-
ing two or more weeks before adjuvant ablation will
allow nearly all the infused radioactivity to decay,
minimizing safety concerns.
Conclusions
This study has demonstrated that adjuvant 90Y PET/
CT-guided ablation may improve tumor absorbed-dose
metrics. These data may justify a prospective clinical
trial to further evaluate this hybrid approach.
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Fig. 5 Linear regression for dose metrics vs tumor volume. a ΔD50
vs tumor volume (Slopefit = −0.046 Gy/cm
3, R2 = 0.505, P = 0.003). b
ΔDavg vs tumor volume (Slopefit = −0.04 Gy/cm
3, R2 = 0.354, P = 0.02).
c ΔV100 vs tumor volume (Slopefit = −0.034%/cm
3,
R2 = 0.615, P = 5.4e−4)
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